Vonicog Alfa News
Vonicog Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Vonicog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or...
- Evidence level: L5
- Predicted indications (20):
- primary release disorder of platelets (100.0%)
- Glanzmann thrombasthenia (100.0%)
- pseudo-von Willebrand disease (100.0%)
- hemophilia (100.0%)
- Scott syndrome (100.0%)
- acquired coagulation factor deficiency (99.9%)
- Von Willebrand disease, X-linked form (99.9%)
- bleeding diathesis due to a collagen receptor defect (99.9%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.9%)
- flood factor deficiency (99.9%)
- hereditary thrombocytosis with transverse limb defect (99.9%)
- familial thrombomodulin anomalies (99.9%)
- von Willebrand disease (99.8%)
- inherited thrombophilia (99.8%)
- small bowel Crohn disease (99.8%)
- methylcobalamin deficiency type cblG (99.8%)
- esophageal ulcer (99.8%)
- gastritis (99.7%)
- thrombotic thrombocytopenic purpura (99.7%)
- hemorrhagic disorder due to a coagulation factors defect (99.6%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.